Aeterna Zentaris announces Pharmanovia has acquired rights to GHRYVELIN

Aeterna Zentaris announced that Pharmanovia, a global lifecycle management healthcare company, has acquired from the Company’s existing EEA and UK partner, Consilient Health, the exclusive rights and license to commercialize GHRYVELIN in the territory for the diagnosis of Adult Growth Hormone Deficiency, AGHD, and, if approved, for Childhood Onset Growth Hormone Deficiency, CGHD. Dr. Klaus Paulini, Chief Executive Officer of Aeterna commented, "Pharmanovia has established global expertise in marketing diagnostic testing solutions in addition to an established footprint in endocrinology across Europe. They are positioned as the natural choice as our commercialization partner moving forward. We believe that the decision by Pharmanovia to invest in GHRYVELIN demonstrates the future potential of GHRYVELIN and is an endorsement of the efforts made to date by both Aeterna Zentaris and our former licensee, Consilient Health’s, to obtain approval for and launch GHRYVELIN in Europe. We are excited to now have Pharmanovia as a partner as we continue our efforts to benefit patients." In 2022, Aeterna Zentaris announced that it will regain full rights to Macrilen for the U.S. and Canada from Novo Nordisk on May 2023 and the Company is actively seeking an alternate development and commercialization partner for Macrilen in the US, Canada and for other territories currently not partnered.